Språk:
Valuta:

1 000 000 kunder har valgt å bruke vår fantastiske tjeneste og høykvalitetsprodukter

  • Få opptil 80 % i rabatt

    Store avslag og salg

  • Rask & verdensomspennende levering

    Motta bestillinger raskt

  • Ingen resepter nødvendig

    Kjøp piller uten noen restriksjoner

  • Pengene tilbake-garanti

    30-dagers refusjon

Doctor
Handlekurven din er tom

Verifisert apotek

Mer enn hundre godkjente sertifiseringer

  • fda
  • fda
  • pgeu gpue
  • mipa
  • cipar
  • mastercard
  • visa
  • mcafee

Banners

Movfor

movfor
  • Movfor 200mg

    Pakke Per pille Spesialpris
    200 kapsel Gratis ekspresslevering $5.49 $1466 -26% Kun $1097
    160 kapsel Gratis ekspresslevering $5.60 $1173 -24% Kun $896
    120 kapsel Gratis ekspresslevering $5.79 $880 -21% Kun $695
    80 kapsel Gratis ekspresslevering $6.18 $587 -16% Kun $494
    40 kapsel Gratis standardlevering $7.33 Kun $293

Product Description

Common use
Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

Dosage and direction

Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days.
Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

Results

Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

Conclusions

Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

Du kan også like:

Abonnere Spesialtilbud og nyheter
Abonnere

testimonials

    5 stars

Tore P “Jeg har aldri vært så fornøyd med en online-tjeneste i mitt liv. Frakten er rask, og tjenesten er enkel og grei å bruke.”

Neste vitnesbyrd